|
POLG2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.30599975278756E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.80859999093985E-09 |
| Normal-vs-Stage2 |
1.60308999999081E-05 |
| Normal-vs-Stage3 |
3.5438318946035E-12 |
| Normal-vs-Stage4 |
1.72869999981451E-07 |
| Stage1-vs-Stage2 |
8.423000E-01 |
| Stage1-vs-Stage3 |
8.564800E-03 |
| Stage1-vs-Stage4 |
1.649410E-01 |
| Stage2-vs-Stage3 |
1.091040E-01 |
| Stage2-vs-Stage4 |
3.822200E-01 |
| Stage3-vs-Stage4 |
6.136600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.94160243438546E-11 |
| Normal-vs-AfricanAmerican |
2.415700E-04 |
| Normal-vs-Asian |
1.968700E-04 |
| Caucasian-vs-AfricanAmerican |
9.253600E-01 |
| Caucasian-vs-Asian |
1.783200E-01 |
| AfricanAmerican-vs-Asian |
4.068800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.73910038884173E-10 |
| Normal-vs-Female |
9.32649513174511E-11 |
| Male-vs-Female |
9.957200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.76559997125503E-10 |
| Normal-vs-Age(41-60Yrs) |
1.0222000024207E-08 |
| Normal-vs-Age(61-80Yrs) |
4.02139999078344E-09 |
| Normal-vs-Age(81-100Yrs) |
7.824000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.173200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.517200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.982000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.416000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.475200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.859000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.07180000000907E-05 |
| Classical-VS-Follicular |
9.195600E-01 |
| Classical-VS-Other |
4.208000E-01 |
| Classical-VS-Normal |
2.64119948134578E-10 |
| Tall-VS-Follicular |
1.015350E-03 |
| Tall-VS-Other |
1.124810E-01 |
| Tall-VS-Normal |
3.0337954370907E-12 |
| Follicular-VS-Other |
5.359400E-01 |
| Follicular-VS-Normal |
2.80699999999356E-06 |
| Other-VS-Normal |
1.238830E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.00299999919551E-08 |
| Normal-vs-N1 |
2.08030000004022E-07 |
| N0-vs-N1 |
2.366200E-01 |
|
|
